BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 23011357)

  • 1. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus.
    Miyawaki S; Nishiyama S; Aita T; Yoshinaga Y
    Mod Rheumatol; 2013 Jul; 23(4):659-66. PubMed ID: 23011357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease).
    Gansauge S; Breitbart A; Rinaldi N; Schwarz-Eywill M
    Ann Rheum Dis; 1997 Jun; 56(6):382-5. PubMed ID: 9227169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up.
    Liao YN; Liu CS; Tsai TR; Hung YC; Chang SJ; Lin HL; Chen YC; Lai HM; Yu SF; Chen CJ
    Kaohsiung J Med Sci; 2011 Jul; 27(7):251-7. PubMed ID: 21757141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus.
    Sun L; Wang D; Liang J; Zhang H; Feng X; Wang H; Hua B; Liu B; Ye S; Hu X; Xu W; Zeng X; Hou Y; Gilkeson GS; Silver RM; Lu L; Shi S
    Arthritis Rheum; 2010 Aug; 62(8):2467-75. PubMed ID: 20506343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus.
    López-Hoyos M; Cabeza R; Martínez-Taboada VM; Crespo J; SanSegundo D; Blanco R; López-Escribano H; Peña M; Rodríguez-Valverde V
    Lupus; 2005; 14(7):505-9. PubMed ID: 16130504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprolactinemia in males with systemic lupus erythematosus.
    Mok CC; Lau CS; Lee KW; Wong RW
    J Rheumatol; 1998 Dec; 25(12):2357-63. PubMed ID: 9858430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A; Stohl W; Schwarting A; Okada M; Scheinberg M; van Vollenhoven R; Hammer AE; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE.
    Tripathy R; Panda AK; Das BK
    Lupus; 2015 Jan; 24(1):82-9. PubMed ID: 25253568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.
    ter Borg EJ; Horst G; Hummel EJ; Limburg PC; Kallenberg CG
    Arthritis Rheum; 1990 May; 33(5):634-43. PubMed ID: 2346519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity.
    Su CC; Shau WY; Wang CR; Chuang CY; Chen CY
    Lupus; 1997; 6(5):449-54. PubMed ID: 9229364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus.
    Miyawaki Y; Sada K; Asano Y; Hayashi K; Yamamura Y; Hiramatsu S; Ohashi K; Morishita M; Watanabe H; Matsumoto Y; Kawabata T; Wada J
    Lupus; 2018 Nov; 27(13):2093-2100. PubMed ID: 30309286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.
    Nasiri S; Karimifar M; Bonakdar ZS; Salesi M
    Rheumatol Int; 2010 Nov; 30(12):1605-9. PubMed ID: 19809816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CII antibody as a novel indicator to assess disease activity in systemic lupus erythematosus.
    He C; Mao T; Feng Y; Song T; Qin C; Yan R; Feng P
    Lupus; 2015 Nov; 24(13):1370-6. PubMed ID: 26048288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
    Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy.
    Sakthiswary R; Suresh E
    Lupus; 2014 Mar; 23(3):225-35. PubMed ID: 24399812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
    Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
    Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus.
    Islam MN; Hossain M; Haq SA; Alam MN; Ten Klooster PM; Rasker JJ
    Int J Rheum Dis; 2012 Feb; 15(1):62-8. PubMed ID: 22324948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between clinical activity and serological markers in a wide cohort of patients with systemic lupus erythematosus: an eight-year prospective study.
    Villegas-Zambrano N; Martínez-Taboada VM; Bolívar A; San Martín M; Alvarez L; Marín MJ; López-Hoyos M
    Ann N Y Acad Sci; 2009 Sep; 1173():60-6. PubMed ID: 19758133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
    Ho A; Barr SG; Magder LS; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.